Navinta Faces New Suit Over Generic Naropin ANDA
APP Pharmaceuticals LLC has taken a new shot at Navinta LLC for attempting to market a generic version of APP's injectable pain management drug Naropin, alleging that such a generic would...To view the full article, register now.
Already a subscriber? Click here to view full article